Konstantinos Syrigos is a Professor, the Head of the 3rd Department of Medicine, and the Chair of the Faculty of Medicine at Athens Medical School, National and Kapodistrian University of Athens. He graduated from the Athens School of Medicine in 1988. He was trained in Internal Medicine at the Laikon University Hospital (Athens University) and in Medical Oncology at the Hammersmith Hospital (London University). He completed his MD thesis with distinction at the Athens School of Medicine in 1995 and his Ph.D. thesis at the Imperial College of Science, Technology and Medicine, London University in 2000. He worked as Senior Registrar in Medical Oncology at the Hammersmith and St Bartholomew’s Hospitals in London and as Consultant at the Sotiria General Hospital in Athens. In 2002, he was appointed Associate Professor of Oncology in Medicine and Head of the Sotiria Oncology Unit. Since 2006, he has also been a Visiting Professor of Thoracic Oncology at Yale University, CT, USA. Since 2012, he has been an Adjunct Professor of Medicine at Pittsburgh School of Medicine, USA. His main fields of interest are targeted therapies, drug development, and thoracic and head and neck oncology.
Dr. Vassilis L. Souliotis currently works at the Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece. He was a Senior Researcher at the Institute of Biological Research and Biotechnology, National Hellenic Research Foundation from 2001 to 2017 and a Research Fellow at the Department of Propaedeutic Internal Medicine and Joint Rheumatology Program, Medical School, National and Kapodistrian, University of Athens since 2017. His research interests focus on the field of cellular DNA damage response (DDR) network, with a longstanding interest in the area of DNA damage formation and repair following exposure to genotoxic agents. He participated in the submission of the research proposal ELMUMY (Elucidation of risk factors and health determinants associated with the progression of Monoclonal Gammopathies to Multiple Myeloma) under Horizon Europe.
HORIZON-MISS-2021-CANCER-02 call. The proposal was selected for funding by the European Commission, and he has coordinated the studies regarding molecular biology and humanized patient-derived in vivo models.
